Why Biotech Startups Need Robust Systems Long Before They Scale
Biotech startups face some of the most challenging conditions in the entire startup landscape. Survival rates for startups are already low but biotechnology ventures the odds are even slimmer. High capital requirements, long development timelines, complex regulatory environments, and specialized equipment increase both risk and cost and it can take years before a product is profitable. These structural challenges are well understood.
What receives far less attention, yet has an equally significant impact on long-term success, is how poorly many biotech startups manage their internal operations. Early-stage companies often underestimate the importance of building reliable systems and processes. While product development is the primary focus, operational efficiency is what allows a biotech company to scale without chaos.
The Hidden Risk: Weak Operational Infrastructure
Biotech teams are usually composed of skilled scientific talent. Founders and early employees do what they do best and enjoy doing; solve technical challenges, advance research, and push innovation forward. Leadership, meanwhile, is focused on fundraising, strategic partnerships, and investor relations. In other words, the attention is on science and capital, the exact place where it should be.
However, a company is more than its lab work. It needs structure, coordination, and repeatability. In many biotech startups, this foundational work is postponed or ignored because operational systems do not appear urgent. As a result, teams default to familiar but inadequate tools. Project plannings are made in Excel, communication goes completely verbally or through WhatsApp, very basic task tracking and routine tasks are done manually every time.
With five people in a room, this works fine and operating can go smoothly. With a small group of people that work closely together, communications is fast and clear, knowledge is shared implicitly, tasks can be tracked without much effort.
Growth Exposes the Weaknesses
The problems surface when the company grows. Once a biotech team reaches 10, 20, or 30 employees, earlier improvisation becomes a liability. New hires do not have the context that early employees relied on. Verbal agreements break down, work begins to duplicate and task updates get lost in the noise. And perhaps worst of all, the shared excel with the planning starts to crash regularly.
These issues impact more than productivity. They introduce operational risk that directly affects:
Experiment timelines
Quality control
Batch documentation
Supply chain coordination
Regulatory compliance
Investor confidence
In a field where accuracy and traceability matter, weak processes can delay development, create errors, and erode credibility.
Why Biotech Startups Need Systems Early
Operational maturity is not something a biotech company can bolt on later without cost. Systems should be built before scaling. Having robust systems in place gives new hires a clear guidance on how to work and where to find information. Furthermore, it reduces the time spend on repetitive work, ensures consistent and accessible operational data tracking, improve productivity by formalizing workflows, reduces errors caused by miscommunication. Another essential reason to make sure clear systems are in place is the compliance with clinical or regulatory requirements to bring a biotech product to market.
Early-stage biotech companies rather spend their time on their core product, assuming that building good systems will consume precious time that could be spend otherwise. In reality, relying on ad-hoc tools slow them down, just not immediately. The inefficiency becomes visible only when the team grows.
Practical Examples of Operational Inefficiency
Consider three common scenarios seen in scaling biotech startups:
Task duplication across teams
Two researchers spend time preparing the same dataset because no shared system clearly assigns responsibilities.
Missed procurement deadlines
A lab runs out of critical reagents because supply needs were tracked in a personal spreadsheet rather than a centralized tool.
Manual reporting that consumes hours
Weekly updates require gathering information manually from WhatsApp chats, emails, and spreadsheets, time that could easily be automated.
Each of these is avoidable with the right operational infrastructure.
How Catalyvia Supports Biotech Companies
Catalyvia helps biotech companies build the systems they should have had from the start. Our work includes identifying the right organizational or project management tools, design workflows that match how your team actually operates, implement automations to optimize your work, create scalable structures that support growth rather than constrain it.
All solutions are customized to the company’s size and way of working, tailored towards your specific needs. The objective is not to add complexity but to create clarity, consistency, and efficiency so scientific progress is supported, not hindered.
Conclusion: Operational Excellence is a Competitive Advantage
Biotech startups do not fail solely because their science is weak. Many fail because their operations cannot keep up with their ambitions. Building strong systems early is not a luxury; it is one of the most effective ways to reduce risk, accelerate development, and prepare the company for scale.
Companies that treat operational maturity as a strategic priority position themselves far better for long-term success.
